# Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients

> **NCT02499367** · PHASE2 · UNKNOWN · sponsor: **The Netherlands Cancer Institute** · enrollment: 84 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Nivolumab
- **RADIATION:** Radiation therapy
- **DRUG:** Low dose doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02499367
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-08
- **Primary completion:** 2023-12
- **Final completion:** 2025-08
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2022-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02499367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02499367, "Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02499367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*